Orgovyx is a novel oral hormone therapy for prostate cancer

By Brian Buntz | July 21, 2021

Orgovyx from Myovant Sciences is a gonadotropin-releasing hormone receptor antagonist that is FDA indicated to treat adults with advanced prostate cancer.

FDA approved the drug in December 2020. In a press release, Richard Pazdur, FDA’s acting director of the Office of Oncologic Diseases, noted that ORGOVYX is “the first oral drug in this class and it may eliminate some patients’ need to visit the clinic for treatments that require administration by a health care provider.”

Pazdur went on to point out that the oral therapy could reduce risk during the COVID-19 pandemic.

Filed Under: Oncology
Tagged With: advanced prostate cancer, gonadotropin-releasing hormone receptor antagonist, Myovant Sciences, Orgovyx

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.